Afatinib for the treatment of advanced non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

Afatinib for the treatment of advanced non-small-cell lung cancer.

Afatinib for the treatment of advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q38197278

about

Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.Sulforaphane Inhibits HIV Infection of Macrophages through Nrf2.Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions.Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers.Afatinib in squamous cell carcinoma of the head and neck.Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.

P2860

Q33633715-6D3806A8-D68F-47D0-9A3C-89407F49E1C0 Q35993749-9F04833F-F251-4460-AA0E-2736EF1CF8B7 Q36383018-BBF795E5-7C2B-400D-A5DA-36A5EAF51C4D Q36847104-0DDB86C8-B202-4E4F-B4C8-ABDAFA87E3CE Q38266308-FF9EEA20-D3AA-4446-A98E-2320EF6A1DE0 Q38575289-3CA14857-9097-4091-9EFC-512DFEE8367F Q38819242-B1BA0634-2570-48E6-8D3B-99E9BFAA649E Q38829891-5E1CF34C-E765-4B5A-8C3E-6C3C6F0BB6F0 Q38862340-B9D7DD86-8B0C-4F10-BE7A-EBD0715FB4F4 Q38945524-44D53BEE-569E-4509-9CBC-22664EB8C44A Q39007500-F5E8F8F8-EDE6-4A76-A1A3-54D9BEFCFF4B

P2860

Afatinib for the treatment of advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q38197278

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Afatinib for the treatment of advanced non-small-cell lung cancer.

@en

type

label

Afatinib for the treatment of advanced non-small-cell lung cancer.

@en

prefLabel

Afatinib for the treatment of advanced non-small-cell lung cancer.

@en

P1433

Q38197278-373F6AE3-75ED-4AED-ABFE-22164A926C16

P1476

Q38197278-9E9F5CD5-5559-4E34-945E-F89371661A68

P2093

Q38197278-143B639A-5BCC-4A60-988E-0E81C3F31F9E

Q38197278-23D37095-BD65-4BC9-A3A0-7E0E21CC9BED

Q38197278-AC09142C-A66D-4E85-B925-3B7BF09E68CC

Q38197278-B1697BD3-05C3-4C37-B369-52C0071D4084

Q38197278-CC36E22C-7B66-48F2-8C81-D44D8A2B5E7E

P2860

Q38197278-0CEFEDE0-BCCC-4395-B361-43C445B70A65

Q38197278-0EB871E7-0025-4C0E-8F16-A4691253E822

Q38197278-0FA0C61B-6685-4BB1-8751-4C0994562A4D

Q38197278-11F3AD59-5ABC-436F-AFB5-4BA2D200DCE1

Q38197278-18088E35-91C6-469F-9768-AAD8A141064E

Q38197278-1D730042-86A2-41D6-87E1-F999BFC00C22

Q38197278-1DFD1DFB-5664-4AFB-8090-800F08B9D015

Q38197278-2381EA59-ADCA-4449-B506-DA532E43C61B

Q38197278-28A44ED9-DA4D-4114-87EA-58E1B6726A40

Q38197278-3386FDFD-14AE-4595-999D-B583E45457C2

P304

Q38197278-D4FC3340-BF35-4F3B-B663-62D28E727797

P31

Q38197278-3913C2FE-1305-47E2-BD43-2D9C52853FE6

P356

Q38197278-617EFFA7-DA6F-4F20-B4DB-D72395765E29

P407

Q38197278-8AC59153-F1A8-4CE3-8796-14EB5C27CE46

P433

Q38197278-341598D0-D123-4AD7-BE47-AC946A0025C5

P478

Q38197278-DA00B978-632F-4198-AAD6-EFE352740672

P50

Q38197278-186D7766-7CE2-4497-9FE4-2E9557D7C2B1

Q38197278-2AAB99D3-B563-41AC-9851-91F9809D90A2

Q38197278-6DDA59A7-1D81-40AD-ABF2-8D8C045556ED

Q38197278-8B7EA1A4-2431-4137-AE71-3B49A84C4CA8

Q38197278-9746466A-E60D-41C0-A2C7-4C7EC4A7C9AD

Q38197278-9A8D98D9-991D-499E-819D-B3E93F4E6C36

Q38197278-F98144FA-E214-4C8E-950A-DB780B485951

P577

Q38197278-85300AD6-C996-44D6-8968-9F2194150E74

P5875

Q38197278-D5FDABC4-00AC-4893-98A9-742CF6C0508D

P698

Q38197278-41A772CC-5D8F-4447-8792-4A78DB21203C

P356

14656566.2014.902445

P1433

Expert Opinion on Pharmacotherapy

P1476

Afatinib for the treatment of advanced non-small-cell lung cancer

@en

P2093

Erika Rijavec

http://www.w3.org/2001/XMLSchema#string

Federica Biello

http://www.w3.org/2001/XMLSchema#string

Francesco Boccardo

http://www.w3.org/2001/XMLSchema#string

Giovanni Burrafato

http://www.w3.org/2001/XMLSchema#string

Giulia Barletta

http://www.w3.org/2001/XMLSchema#string

P2860

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Screening for epidermal growth factor receptor mutations in lung cancer

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

P304

889-903

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2014.902445

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Grossi

Giovanna Dal Bello

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260948818

http://www.w3.org/2001/XMLSchema#string

P698

24646054

http://www.w3.org/2001/XMLSchema#string